CS Paper Radar

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza

cs.AI ·submitted 2026-10-30 13:17 UTC · v1
benchmark

Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

Closest papers

Nearest neighbours by meaning across the whole index.

Detecting Spin in Clinical Trials with Large Language Models

cs.CL ·2026-10-08 ·Tjaš Ajdovec, Marko Robnik-Šikonja, Simon Šuster
publishedcode/data similarity 0.70
Abstract · 5 pages, 1 figure, 2 tables. Accepted at the 29th International Multiconference Information Society (IS 2026), AI in Healthcare track, Ljubl…

Spin in clinical trials includes reporting practices that distort the presentation of results. This is particularly critical in medicine, where spin is present in more than 50% of randomized controlled trials that fail to reach statistical significance. The comparison of primary and reported outcomes is crucial for detecting several types of spin, including outcome switching. We used 300 pairs of outcomes labeled with semantic similarity to develop a system for automatic detection of outcome switching. We evaluated baseline text similarity models and open-source LLMs using generated similarity scores and the Youden index to determine the classification threshold. The proposed approach involves prompt engineering, classification based on token probabilities, and majority voting for the final decision. The results on the test set of 2,496 examples with an F1 score of 0.78 and an accuracy of 0.90 outperform baseline text similarity models but trail behind fine-tuned versions of BERT. We used LLMs to generate natural language explanations for the classified instances and manually assessed their quality.

0.38

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.70
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.56

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

cs.LG ·2026-11-06 ·Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains
code/data similarity 0.70
Abstract · 38 pages. Code: https://github.com/oibrahi1/TrialJev. Models: https://huggingface.co/omareng/TrialJev

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

0.22

Disease-level drug approval forecasting from trial-agnostic public data

cs.LG q-bio.QM ·2026-09-29 ·Samir Townsley, Pagkratios Tagkopoulos, Ilias Tagkopoulos
similarity 0.67
Abstract

Drug development is an expensive and lengthy process requiring developers to select drugs for human trials and diseases to target. Computational tools that can estimate before testing which drug-disease candidates are most likely to reach FDA approval could reduce development time and costs through early program advancement and disease prioritization. Yet existing approaches predict outcomes at a single level or stage or do not distinguish between disease outcomes for the same drug. We ask (1) whether FDA approval can be forecast for a drug-disease pair using only pre-clinical trial information, and (2) whether these forecasts can help prioritize diseases for the same drug. We built a cohort of 14,134 drug-disease pairs by reconstructing programs from ClinicalTrials.gov, extracting disease-level approvals from FDA label documentation, and enriching each pair with molecular, disease, ADMET, target, and pathway features. We divided the cohort into pre- and post-2019 programs and trained a classifier on pre-2019 data to predict FDA approval. On the post-2019 cohort (2,637 programs), the model would have prioritized a program that ultimately gained approval over one that did not approximately three out of four times. For drugs tested across multiple diseases, selecting the model's highest-ranked disease would have identified an ultimately approved disease 61.3% of the time, compared with 40.7% under random selection. These results show that public pre-trial information contains signal for forecasting FDA approval at the drug-disease level and can help prioritize diseases for the same drug. We provide a public web tool for SMILES- and ICD-10-based drug-disease approval forecasting.

0.14

Evaluating Pretrained Language Semantics for Structured EHR Prediction Tasks

cs.CL cs.LG ·2026-11-12 ·Ashvin Gupta, Brendan Delaney, Alessandra Russo
top venue similarity 0.67
Abstract · Accepted for publication in Proceedings of Machine Learning Research (PMLR), Vol. 346, 2026

Structured Electronic Health Record (EHR) models typically represent clinical concepts as dataset-specific tokens, discarding their associated natural-language semantics. Consequently, relationships between concepts must largely be learned from EHR co-occurrence without directly exploiting pretrained linguistic knowledge. We investigate the contribution of pretrained language semantics to longitudinal EHR prediction through tEHR, a framework that converts clinical events into natural-language descriptions and adapts pretrained autoregressive language models through EHR-specific continued pretraining and task-specific discriminative fine-tuning. We evaluate tEHR across four MIMIC-IV prediction tasks, where Mistral-7B achieves the strongest overall performance against structured-data, code-based, and LLM-based baselines. Controlled ablations demonstrate the importance of lexical grounding, numerical values, and both adaptation stages. A capacity-controlled experiment further shows that replacing clinical descriptions with atomic code tokens substantially reduces performance despite retaining the same LLM backbone. Alternative approaches incorporating pretrained semantic embeddings offer lower computational costs but do not match full textualisation. These results highlight the importance of both semantic representation and downstream adaptation when applying pretrained language models to structured EHR prediction.

0.29

A primer on evaluation methods for large language models in healthcare

cs.CL cs.AI ·2026-09-13 ·Suzannah E McKinney, Phuc Vu, Samuel A Justice, Christopher Humphries, Alyssa Pradhan +8 more
similarity 0.66
Abstract

Large language models (LLMs) have a growing range of applications in medicine, and their evaluation is critical for ensuring they provide benefit and not harm. This evaluation can be more challenging than traditional machine learning for many reasons, including probabilistic and open-ended outputs, and behavior that shifts with prompt design and accumulated context. This review covers four key areas of LLM evaluation: principles of study design, statistical methods, capability evaluation and clinical application evaluation. Capability evaluation considers different benchmarks, including multiple-choice, agentic and multi-turn benchmarks, alongside operational metrics like token usage and latency. Clinical application evaluation addresses establishing accuracy of free text outputs, such as human review and LLM-as-a-judge, and clinical trial approaches. Across sections, we describe underlying concepts and potential pitfalls, while emphasizing the importance of aligning evaluation methods with the research question. Together, this article aims to provide a pragmatic basis for designing and executing rigorous evaluations of healthcare LLMs.

0.15

An Agentic Generative Large Language Model for Treatment Planning of Colorectal Cancer

cs.CL ·2026-08-10 ·Mengxian Lyu, Cheng Peng, Tim Jang, Ang Li, Mengyuan Zhang +16 more
code/data similarity 0.66
Abstract

Treatment planning in precision oncology requires synthesizing heterogeneous patient information with rapidly evolving clinical guidelines to ensure guideline-concordant care. While large language models (LLMs) show promise in many diagnostic tasks, their adoption for high-stakes treatment planning is hindered by complex reasoning, adherence to timely clinical guidelines, and safety concerns. In this study, we present GatorOnco, an agentic LLM for colorectal cancer (CRC) treatment planning. GatorOnco is developed using a total of 282 billion tokens of biomedical text, including healthcare system-scale clinical text comprising 166 billion tokens from UF Health. We implemented a domain-adaptation method that integrates pre-training, model merging, a two-stage post-training approach, and agent-based reinforcement learning. An agentic retrieval-augmented generation (RAG) approach dynamically integrates time-sensitive clinical guidelines into the reasoning process. In a blind, randomized clinical evaluation conducted by five UF Health oncologists, GatorOnco significantly outperformed open-source LLMs (P < 0.01) and achieved expert-level performance comparable to UF Health oncologists. Compared with expert oncologists, GatorOnco received significantly higher ratings for readability (4.46 vs. 4.19, P < 0.01) and completeness (3.91 vs. 3.52, P < 0.01), while showing statistically comparable performance in correctness (4.09 vs. 4.11, P = 0.921), currency (4.04 vs. 3.98, P = 0.478), and safety (4.22 vs. 4.22, P = 0.999). These findings demonstrate that integrating agentic reasoning with large-scale domain adaptation can help bridge the gap for generative AI in high-stakes cancer treatment planning.

0.50

Defining and Categorising Human-AI Interactions in Clinical Trials: A Multidimensional Human-AI Classification Approach

cs.AI ·2026-09-29 ·Sandra Woolley, Tim Collins, Khalid Khattak, Illia Chernomorets, Ariane Arevalo +1 more
similarity 0.66
Abstract · 16 pages

This paper examines human-AI interactions (HAIIs) in clinical trials and presents a multidimensional categorisation framework that classifies interactions according to AI tasks, human-AI relationships, interaction configurations and interacting human groups. We define HAII, examine existing taxonomies and extend existing categorisation approaches through this novel multidimensional framework. We purposively sampled 15 clinical trials from a previously reported dataset. Each trial was independently categorised by two human reviewers and six large language model (LLM) classifiers. The proposed categorisation provides a structured method for the consistent identification, comparison and synthesis of human-AI interactions across clinical-trial records. The framework is intended to support more consistent comparison and synthesis of AI-related clinical trials and to make explicit the different forms of human involvement associated with AI interventions. The results demonstrate the potential for LLM-assisted categorisation while indicating the continuing importance of human judgement where trial records are incomplete or ambiguous. The principal contribution is a proposed multidimensional framework that brings together AI tasks, human-AI relationships, interaction configurations and interacting human groups within a single approach designed for clinical-trial records. Its significance lies in its potential to support more systematic identification, comparison and synthesis of how humans and AI interact in clinical trials.

0.22